Update on Quinidine and Procainamide

Cohen, Martin N.
July 1982
Angiology;Jul1982, Vol. 33 Issue 7, p454
Academic Journal
The article presents an update on Quinidine and Procainamide. Arrhythmia understanding and management is participating in the explosion of medical information and investigational techniques. New drugs are being introduced, such as disopyramide, verapamil, tocainide, mexiletine, aprindine, and amiodarone, which are available in hospital formularies or through research protocols. Quinidine gluconate and sustained release forms have a slower time to peak absorption and permit even longer dosing intervals, such as 300 to 600 mg q8h.


Related Articles

  • Clinical Significance of Heart Rhythm Disorders. Burch, G.E. // Angiology;Mar1978, Vol. 29 Issue 3, p187 

    Provides information on the clinical significance of heart rhythm disorders. Two fundamental types of cardiac states involving arrhythmias; Drugs used of arrhythmias; Use of carotid sinus pressure to stop supraventricular tachycardia.

  • Sarcomere Control Mechanisms and the Dynamics of the Cardiac Cycle. Solaro, R. John // Journal of Biomedicine & Biotechnology;2010, p1 

    This review focuses on recent developments in the molecular mechanisms by which Ca activates cardiac sarcomeres and how these mechanisms play out in the cardiac cycle. I emphasize the role of mechanisms intrinsic to the sarcomeres as significant determinants of systolic elastance and ventricular...

  • Review: reduction in resting heart rate after taking β-blockers or calcium- channel blockers reduce mortality and morbidity after Ml. Good, Christopher W.; Berger, Peter B. // Evidence Based Medicine;Aug2008, Vol. 13 Issue 4, p112 

    The article presents findings from various studies on the significance of reduction in resting heart rate (HR) after treatment with beta-blockers (BBs) or calcium-channel blockers (CCBs). The studies investigate the relation between resting HR and all-cause mortality, cardiac death,...

  • Preface [Hot topic: Anti-arrhythmic Drugs (Guest Editors: Uwe Gerlach & Heinrich C. Englert)]. Gerlach, Uwe; Englert, Heinrich C. // Current Medicinal Chemistry - Cardiovascular & Hematological Age;Oct2003, Vol. 1 Issue 3, p1 

    Arrhythmias are considered to be an important risk factor, which significantly contributes to mortality and morbidity of cardiovascular patients. However, presently available antiarrhythmic drugs are not generally accepted as a means for risk reduction, mainly due to proarrhythmic side effects...

  • Maternal arrhythmias during pregnancy. Ferrero, Simone; Colombo, Barbara Maria; Ragni, Nicola // Archives of Gynecology & Obstetrics;May2004, Vol. 269 Issue 4, p244 

    Introduction.. An increased incidence of maternal cardiac arrhythmias is observed during pregnancy and they can range from clinically irrelevant isolated premature beats to debilitating supraventricular and ventricular tachycardias. Discussion.. Management of arrhythmias during pregnancy is...

  • EVALUATION OF A NEW QUINIDINE COMPOUND: A COMPARATIVE STUDY. Pote, Harry H. // Angiology;Jul1961, Vol. 12 Issue 7, p320 

    Twenty-five patients with various cardiac arrhythmias were treated with a new quinidine salt, quinidine polygalacturonate. The usual daily dosage was one 275-mg tablet. Duration of therapy averaged 133 days In 50 per cent of the patients, quinidine polygalacturonate provided more satisfactory...

  • Amlodipine reduces CV events in CAD patients with normal BP.  // Formulary;Jan2005, Vol. 40 Issue 1, p11 

    Reports on the link of calcium antagonist amlodipine to the reduction of cardiovascular events in patients with coronary artery disease. Benefit of the decrease of blood pressure on atherosclerosis; Comparison of intravascular ultrasound with atheroma volume.

  • Selected cardiovascular agents.  // Formulary;Jan2005, Vol. 40 Issue 1, p32 

    Presents information on selected cardiovascular agents available in the United States. Azimilide; Dronedarone; Tecadenoson; Tedisamil; Enoximone; Oxypurinol; Tolvaptan.

  • LONG TERM MEDICAL TREATMENT OF STABLE CORONARY DISEASE. Shavelle, David M. // Heart;Nov2007, Vol. 93 Issue 11, p1473 

    The article provides information on the medical treatment for stable coronary artery disease (CAD). The medical management of patients with stable CAD include the use of aspirin, beta-blockers, nitrates and statins. Calcium channel blockers can be added if patients remain symptomatic or used...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics